Findings

What do systematic reviews say?

191 questions · 196 findings · 20 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 65 · 33.2%GRADE not reported 9 · 4.6%Very low 26 · 13.3%Low 46 · 23.5%Moderate 36 · 18.4%High 14 · 7.1%

NSAIDs vs placebo

Annual rate of change in % predicted FVC All participants · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 226 participants
Moderate

NSAIDs vs placebo

Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Moderate

NSAIDs vs placebo

Annual rate of change in % predicted FVC Subgroup: Over 13 years of age · adults and children with cystic fibrosis

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Moderate

NSAIDs vs placebo

Transmission‐related outcomes: hospitalization ‐ Number or proportion of hospital admissions · adults and children with cystic fibrosis

Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).

1 finding from 1 review

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
OR 0.61 [0.37, 1.01]
4 studies · 286 participants
Moderate

Intervention not reported

Change in weight (kg):1 at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate

Intervention not reported

Change in height (cm):1 at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate

Intervention not reported

Change in total calories (Kcal/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Change in total protein (g/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Change in total fat (g/day): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Intervention not reported

Adverse events: · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Intervention not reported

Change in lung function ‐ FEV₁ (% predicted): at 12 months · adults and children with cystic fibrosis

1 finding from 1 review

Oral calorie supplements for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low